According to a research report published by Citigroup, Kang Fang Biotech's mid-term Harmoni-2 readings show that iVonesScimab, as a first-line single-agent treatment for PD-L1 positive non-small cell lung cancer, has shown significant overall survival efficacy compared to pembrolizumab and strengthens its differentiated positioning. Global readings are still the key. The bank has a positive view of people with high PD-L1 expression of Harmoni-7 globally and people with squamous non-small cell lung cancer, and is optimistic about the transformation of the company's future tests from China to the global market; key catalysts for the second half of the year include the prescription drug user payment law decision and Harmoni-3 readings. The bank maintained Kangfang Biotech's “buy” rating, and the target price remained unchanged at HK$171.

According to a research report published by Citigroup, Kang Fang Biotech's mid-term Harmoni-2 readings show that iVonesScimab, as a first-line single-agent treatment for PD-L1 positive non-small cell lung cancer, has shown significant overall survival efficacy compared to pembrolizumab and strengthens its differentiated positioning. Global readings are still the key. The bank has a positive view of people with high PD-L1 expression of Harmoni-7 globally and people with squamous non-small cell lung cancer, and is optimistic about the transformation of the company's future tests from China to the global market; key catalysts for the second half of the year include the prescription drug user payment law decision and Harmoni-3 readings. The bank maintained Kangfang Biotech's “buy” rating, and the target price remained unchanged at HK$171.